The flavivirus protease as a target for drug discovery

Matthew Brecher, Jing Zhang, Hongmin Li

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations

Abstract

Many flaviviruses are significant human pathogens causing considerable disease burdens, including encephalitis and hemorrhagic fever, in the regions in which they are endemic. A paucity of treatments for flaviviral infections has driven interest in drug development targeting proteins essential to flavivirus replication, such as the viral protease. During viral replication, the flavivirus genome is translated as a single polyprotein precursor, which must be cleaved into individual proteins by a complex of the viral protease, NS3, and its cofactor, NS2B. Because this cleavage is an obligate step of the viral life-cycle, the flavivirus protease is an attractive target for antiviral drug development. In this review, we will survey recent drug development studies targeting the NS3 active site, as well as studies targeting an NS2B/NS3 interaction site determined from flavivirus protease crystal structures.

Original languageEnglish (US)
Pages (from-to)326-336
Number of pages11
JournalVirologica Sinica
Volume28
Issue number6
DOIs
StatePublished - Dec 2013
Externally publishedYes

Keywords

  • Flavivirus
  • Inhibitor
  • Protease

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Virology

Fingerprint

Dive into the research topics of 'The flavivirus protease as a target for drug discovery'. Together they form a unique fingerprint.

Cite this